{"doi":"10.1002/med.21765","title":"Understanding the tumor microenvironment for effective immunotherapy","abstract":"<jats:title>Abstract</jats:title><jats:p>Advances in immunotherapy have led to durable and long‐term benefits in a subset of patients across a number of solid tumor types. Understanding of the subsets of patients that respond to immune checkpoint inhibitors at the cellular level, and in the context of their tumor microenvironment (TME) is becoming increasingly important. The TME is composed of a heterogeneous milieu of tumor and immune cells. The immune landscape of the TME can inhibit or promote tumor initiation and progression; thus, a deeper understanding of tumor immunity is necessary to develop immunotherapeutic strategies. Recent developments have focused on characterizing the TME immune contexture (type, density, and function) to discover mechanisms and biomarkers that may predict treatment outcomes. This has, in part, been powered by advancements in spatial characterization technologies. In this review article, we address the role of specific immune cells within the TME at various stages of tumor progression and how the immune contexture determinants affecting tumor growth are used therapeutically.</jats:p>","journal":"Medicinal Research Reviews","year":2021,"id":654415,"datarank":0.8739000161070676,"base_score":5.82600010738045,"endowment":5.82600010738045,"self_citation_contribution":0.8739000161070676,"citation_network_contribution":0.0,"self_endowment_contribution":0.8739000161070676,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":338,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":17,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1352674,"name":"James Monkman","orcid":"0000-0002-7219-8402","position":1,"is_corresponding":false},{"id":1172193,"name":"Majid Ebrahimi Warkiani","orcid":"0000-0002-4184-1944","position":2,"is_corresponding":false},{"id":874376,"name":"Rahul Ladwa","orcid":null,"position":3,"is_corresponding":false},{"id":850684,"name":"Kenneth J. O’Byrne","orcid":"0000-0002-6754-5633","position":4,"is_corresponding":false},{"id":6925,"name":"Nima Rezaei","orcid":"0000-0002-3836-1827","position":5,"is_corresponding":false},{"id":773968,"name":"Arutha Kulasinghe","orcid":"0000-0003-3224-7350","position":6,"is_corresponding":false},{"id":1707913,"name":"Habib Sadeghi Rad","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Understanding the tumor microenvironment for effective immunotherapy","abstract":"<jats:title>Abstract</jats:title><jats:p>Advances in immunotherapy have led to durable and long‐term benefits in a subset of patients across a number of solid tumor types. Understanding of the subsets of patients that respond to immune checkpoint inhibitors at the cellular level, and in the context of their tumor microenvironment (TME) is becoming increasingly important. The TME is composed of a heterogeneous milieu of tumor and immune cells. The immune landscape of the TME can inhibit or promote tumor initiation and progression; thus, a deeper understanding of tumor immunity is necessary to develop immunotherapeutic strategies. Recent developments have focused on characterizing the TME immune contexture (type, density, and function) to discover mechanisms and biomarkers that may predict treatment outcomes. This has, in part, been powered by advancements in spatial characterization technologies. In this review article, we address the role of specific immune cells within the TME at various stages of tumor progression and how the immune contexture determinants affecting tumor growth are used therapeutically.</jats:p>","is_dataset_classified":null,"base_score":5.82600010738045,"endowment":5.82600010738045,"datacite_reuse_total":17,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33277742","pmcid":"PMC8247330","openalex_id":"https://openalex.org/W3108853735","authors":[],"funders":[],"total_grants":0,"fwci":9.2888,"citation_percentile":0.98618983,"influential_citations":0,"citation_trend":[{"year":2013,"count":1},{"year":2020,"count":2},{"year":2021,"count":10},{"year":2022,"count":54},{"year":2023,"count":50},{"year":2024,"count":106},{"year":2025,"count":79},{"year":2026,"count":36}],"oa_status":"hybrid","license":"cc-by-nc","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/med.21765","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/med.21765","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/med.21765","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/med.21765","host_type":"publisher"},{"url":"https://doi.org/10.1002/med.21765","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33277742","host_type":"repository"},{"url":"https://eprints.qut.edu.au/207030/1/med.21765.pdf","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8247330","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC8247330","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC8247330?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","Immunotherapy and Immune Responses","Immune cells in cancer","Humans","Immunotherapy","Neoplasms","Tumor Microenvironment"],"mesh_terms":["Humans","Immunotherapy","Neoplasms","Tumor Microenvironment"],"keywords":["Tumor microenvironment","Immune system","Immunotherapy","Context (archaeology)","Tumor progression","Biology","Immune checkpoint","Immunity","Cancer research","Immunology","Cancer","Biomarkers","Immune Checkpoint Inhibitors","Immune Contexture"],"sdg_mappings":[],"linked_datasets":[{"doi":"10.6084/m9.figshare.26753260.v1","title":"Additional file 5 of Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26702152","title":"Additional file 1 of Crosstalk between metabolism and cell death in tumorigenesis","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.26702152.v1","title":"Additional file 1 of Crosstalk between metabolism and cell death in tumorigenesis","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.26702155","title":"Additional file 2 of Crosstalk between metabolism and cell death in tumorigenesis","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.26702155.v1","title":"Additional file 2 of Crosstalk between metabolism and cell death in tumorigenesis","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.26674523.v1","title":"Additional file 2 of Frozen tissue coring and layered histological analysis improves cell type-specific proteogenomic characterization of pancreatic adenocarcinoma","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.26674520","title":"Additional file 1 of Frozen tissue coring and layered histological analysis improves cell type-specific proteogenomic characterization of pancreatic adenocarcinoma","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.26674523","title":"Additional file 2 of Frozen tissue coring and layered histological analysis improves cell type-specific proteogenomic characterization of pancreatic adenocarcinoma","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.26674520.v1","title":"Additional file 1 of Frozen tissue coring and layered histological analysis improves cell type-specific proteogenomic characterization of pancreatic adenocarcinoma","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.25792782","title":"Additional file 1 of METTL14 regulates CD8+T-cell activation and immune responses to anti‐PD‐1 therapy in lung cancer","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.25792782.v1","title":"Additional file 1 of METTL14 regulates CD8+T-cell activation and immune responses to anti‐PD‐1 therapy in lung cancer","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.22949328.v1","title":"Additional file 1 of Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.22949331","title":"Additional file 2 of Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.22949331.v1","title":"Additional file 2 of Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.22949328","title":"Additional file 1 of Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.22631484.v1","title":"Additional file 1 of Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer","publisher":"figshare","resource_type":"Dataset"},{"doi":"10.6084/m9.figshare.22631484","title":"Additional file 1 of Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer","publisher":"figshare","resource_type":"Dataset"}],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T06:30:22.851380Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}